Top 5 Stock Picks of Hal Mintz’s Sabby Capital

3. Sorrento Therapeutics, Inc. (NASDAQ:SRNE)

Sabby Capital’s Stake Value: $12.95 million

Percentage of Sabby Capital’s 13F portfolio: 1.75%

Total Number of Hedge Fund Holders: 10

Next up is Sorrento Therapeutics, Inc. (NASDAQ: SRNE), a commercial biopharmaceutical company which develops therapies for autoimmune, cancer, viral and neurodegenerative diseases. The company is based in California, and operates through its two segments: Sorrento Therapeutics and Scilex.

For the third quarter of 2021, Sorrento Therapeutics, Inc. (NASDAQ: SRNE) posted an EPS of -$0.40, missing estimates by -$0.11. The company raked in $12.06 million in quarterly revenue, missing analysts’ forecasts by $4.84 million.

As of Q3 2021, 10 hedge funds out of 867 tracked by Insider Monkey reported owning positions worth $42.58 million in Sorrento Therapeutics, Inc. (NASDAQ: SRNE). This shows a bullish trend from the previous quarter where the same number of hedge funds held positions with a combined value of $39.34 million in the pharmaceutical company.